| Old Articles: <Older 6411-6420 Newer> |
|---|
 |
Chemistry World
June 21, 2010
Sarah Houlton |
Recalling pharma Recent drug withdrawals and manufacturing failures have highlighted the importance of ensuring that the medicines patients take contain what it says on the label.   |
The Motley Fool
June 21, 2010
Luke Timmerman |
Bristol-Myers Dumps Exelixis Drug There is an exit payment for Exelixis. |
The Motley Fool
June 21, 2010
Julie Clarenbach |
Which Drugmaker Is a Buy? A look at some numbers to weigh one against another. |
The Motley Fool
June 21, 2010
Jordan DiPietro |
Covidien Management Staying Busy The medical device company is on an acquisition spree as of late. |
The Motley Fool
June 21, 2010
Erin Kutz |
Curis Misses Mark in Drug Trial; Genzyme Elects Board; GTC Cuts Jobs; and More Boston-Area Life Sciences News These drug and biomedical companies made news last week. |
The Motley Fool
June 21, 2010
Luke Timmerman |
Stanford Biodesign, a Hothouse for Medical Devices, Shares its Secret Sauce for Invention How do you measure an innovation's worth? By the real patients it helps. |
InternetNews
June 18, 2010 |
Solid Growth Seen for Health Care IT Sector Key contributor to revenue growth will be the government's push to electronically store patients' medical records. |
The Motley Fool
June 18, 2010
Brian Orelli |
Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed. |
The Motley Fool
June 18, 2010
Brian Orelli |
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday. |
The Motley Fool
June 18, 2010
Denise Gellene |
San Diego's Neurocrine Biosciences Scores Second Big Deal in Two Days The San Diego biotech agreed to grant German drug maker Boehringer Ingelheim and signed a pact with Abbott Labs. |
| <Older 6411-6420 Newer> Return to current articles. |
